{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:27:59Z","timestamp":1790756879057,"version":"4.1.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec id=\"ab-eoi220081-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Tumor necrosis factor inhibitors (TNFis) can induce antidrug antibody (ADA) formation and loss of therapeutic response. However, the utility of ADA testing and the association between ADAs and treatment response in patients with noninfectious uveitis (NIU) is not well understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220081-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the frequency of ADAs and their association with drug levels and clinical response in patients with NIU treated with adalimumab or infliximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220081-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cross-sectional study included patients diagnosed with NIU who received adalimumab or infliximab and underwent testing for serum drug level and ADAs at the National Eye Institute from September 2017 to July 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220081-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Serum drug level testing with reflex testing for ADA levels was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220081-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The main outcome was the association between drug levels and ADAs, clinical response, and concurrent antimetabolite use in patients treated with TNFis for NIU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220081-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 54 patients included in the study, 42 received adalimumab (mean [SD] age, 43.6 [19.6] years; 25  [59.5%] female) and 12 received infliximab (mean [SD] age, 42.7 [20.4] years; 7 [58.3%] male). In the adalimumab group, mean (SD) drug level was 9.72 (6.82) \u03bcg\/mL, mean (SD) ADA level was 84.2 (172.9) arbitrary units\/mL, and ADA frequency was 35.7% (15 of 42 patients). Mean drug level was lower in those with ADAs compared with those without ADAs (mean [SD], 2.8 [2.6] \u03bcg\/mL vs 13.6 [5.2] \u03bcg\/mL; difference: 10.8 \u03bcg\/mL; 95% CI, 8.3-13.2 \u03bcg\/mL;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). There was a higher mean drug level with concurrent antimetabolite use compared with monotherapy (mean [SD], 11.0 [7.3] \u03bcg\/mL vs 6.8 [4.5] \u03bcg\/mL; difference: \u20134.2 \u03bcg\/mL; 95% CI, \u20138.7 to 0.2 \u03bcg\/mL;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.06). Multivariable modeling showed that a 1\u2212arbitrary unit increase in ADAs was associated with a \u20130.02 \u03bcg\/mL (95% CI, \u20130.01 to \u20130.34 \u03bcg\/mL) difference in mean drug level (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Favorable clinical response was associated with a threshold drug level above 2.7 \u03bcg\/mL or an antibody level below 15.2 \u03bcg\/mL. The mean (SD) drug level in the infliximab group was 27.02 (18.15) \u03bcg\/mL, and no ADAs were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220081-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this study, 35.7% of adalimumab-treated patients with NIU had ADAs. The presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi treatment failure. Although limited by the retrospective design, our results suggest that therapeutic drug monitoring may be considered among patients experiencing therapy failure to help exclude ADAs as a potential cause of treatment failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.5584","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T11:33:33Z","timestamp":1671708813000},"page":"150","source":"Crossref","is-referenced-by-count":34,"title":["Antidrug Antibodies to Tumor Necrosis Factor \u03b1 Inhibitors in Patients With Noninfectious Uveitis"],"prefix":"10.1001","volume":"141","author":[{"given":"Sunil","family":"Bellur","sequence":"first","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McHarg","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijak","family":"Kongwattananon","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Vitale","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Nida","family":"Sen","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Kodati","sequence":"additional","affiliation":[{"name":"National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"eoi220081r1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis.","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"eoi220081r2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"eoi220081r3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network.","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"eoi220081r4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/ICU.0000000000000562","article-title":"Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.","volume":"30","author":"Thomas","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"eoi220081r5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","article-title":"Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.","volume":"104","author":"Skrabl-Baumgartner","year":"2019","journal-title":"Arch Dis Child"},{"issue":"12","key":"eoi220081r6","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","article-title":"Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies.","volume":"123","author":"Cordero-Coma","year":"2016","journal-title":"Ophthalmology"},{"key":"eoi220081r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2021.1936565","article-title":"Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case series.","volume":"1-5","author":"McKay","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"eoi220081r8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors.","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"eoi220081r9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis.","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"issue":"2","key":"eoi220081r10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10067-019-04798-6","article-title":"Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.","volume":"39","author":"Brunelli","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"7","key":"eoi220081r11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy.","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"eoi220081r12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease.","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"eoi220081r13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1517\/14712598.2013.848194","article-title":"Immunogenicity of anti-TNFa therapy in psoriasis: a clinical issue?","volume":"13","author":"De Simone","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"eoi220081r14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/17425255.2017.1377180","article-title":"Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.","volume":"13","author":"Wong","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"eoi220081r15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"eoi220081r16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"eoi220081r17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"eoi220081r18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00384-021-03855-4","article-title":"The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease.","volume":"36","author":"Mc Gettigan","year":"2021","journal-title":"Int J Colorectal Dis"},{"issue":"2-3","key":"eoi220081r19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of anti-TNF-a agents in autoimmune diseases.","volume":"38","author":"Emi Aikawa","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"eoi220081r20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides.","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology"},{"key":"eoi220081r21","article-title":"Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study.","author":"Sejournet","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"eoi220081r22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease.","volume":"13","author":"Papamichael","year":"2019","journal-title":"J Crohns Colitis"},{"key":"eoi220081r23","first-page":"115","article-title":"Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study.","volume":"14","author":"Pedersen","year":"2020","journal-title":"Biologics"},{"issue":"1","key":"eoi220081r24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","article-title":"Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.","volume":"52","author":"Martelli","year":"2017","journal-title":"J Gastroenterol"},{"issue":"3","key":"eoi220081r25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.gtc.2017.05.014","article-title":"Update on therapeutic drug monitoring in crohn\u2019s disease.","volume":"46","author":"Heron","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"eoi220081r26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2799977\/jamaophthalmology_bellur_2022_oi_220081_1675440839.80478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T11:02:21Z","timestamp":1676545341000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2799977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.5584","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}